Stay updated with breaking news from Leslie Pott. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biosimilar Tyruko® approved for all indications of reference medicine, as first and only biosimilar to treat relapsing forms of multiple sclerosis in EuropeDecision based on evidence from extensive...
Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical data Breast and gastric cancers are among most common types of cancer, accounting together for nearly...
Mylight study met its primary efficacy endpoint and showed no clinically meaningful differences to reference afliberceptResults offer hope of new...
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026 New end-to-end drug substance and drug...
Sandoz well positioned to deliver continued mid-single digit sales growth; core EBITDA margin of 24-26% and Free Cash Flow to more than double over mid...